Agenus to Host Conference Call to Discuss Global Alliance with Incyte Corporation Today at 8:30 a.m. EST
09 January 2015 - 11:26PM
Business Wire
Agenus Inc. (Nasdaq: AGEN) will host a conference call today to
discuss its global license, development and commercialization
agreement with Incyte Corporation (Nasdaq: INCY) for novel
immuno-oncology antibodies, which was announced earlier this
morning.
The call will begin at 8:30 a.m. EST. To access the live call,
dial 877-741-5270. A replay will be available approximately two
hours after the call and will remain available for 60 days. The
replay number is 404-537-3406, and the access code is 31833.
About Agenus
Agenus is an immuno-oncology company developing a portfolio of
checkpoint modulators (CPMs), heat shock protein peptide-based
vaccines and adjuvants. Agenus’ checkpoint modulator programs
target GITR, OX40, CTLA-4, LAG-3, TIM-3 and PD-1. The company’s
proprietary discovery engine Retrocyte DisplayTM is used to
generate fully human and humanized therapeutic antibody drug
candidates. The Retrocyte DisplayTM platform uses a high-throughput
approach incorporating IgG format human antibody libraries
expressed in mammalian B-lineage cells. Agenus’ heat shock
protein-based vaccines for cancer and infectious disease have
completed Phase 2 studies in glioblastoma multiforme, and in the
treatment of herpes simplex viral infection. The company’s QS-21
Stimulon® adjuvant platform is extensively partnered with
GlaxoSmithKline and Janssen Sciences Ireland UC and includes
several vaccine candidates in Phase 2, as well as shingles and
malaria vaccines which have successfully completed Phase 3 clinical
trials. For more information, please visit www.agenusbio.com, or
connect with the company on Facebook, LinkedIn, Twitter and
Google+.
Forward-Looking Statement
This press release contains forward-looking statements that are
made pursuant to the safe harbor provisions of the federal
securities laws, including statements regarding the global alliance
with Incyte Corporation. These forward-looking statements are
subject to risks and uncertainties that could cause actual results
to differ materially from those projected. These risks and
uncertainties include, among others, regulatory approval of the
transaction, as well as the factors described under the Risk
Factors section of our most recently filed Quarterly Report on Form
10-Q with the Securities and Exchange Commission. Agenus cautions
investors not to place considerable reliance on the forward-looking
statements contained in this release. These statements speak only
as of the date of this document, and Agenus undertakes no
obligation to update or revise the statements, other than to the
extent required by law. All forward-looking statements are
expressly qualified in their entirety by this cautionary
statement.
BMC CommunicationsBrad Miles,
646-513-3125bmiles@bmccommunications.com
Agenus (NASDAQ:AGEN)
Historical Stock Chart
From Apr 2024 to May 2024
Agenus (NASDAQ:AGEN)
Historical Stock Chart
From May 2023 to May 2024